United States: Private Ruling Endorses Taxpayer-Friendly Reading Of "Qualified Small Business" Under Section 1202

On September 5, 2014, the Internal Revenue Service ("IRS") released Private Letter Ruling 201436001 (the "Ruling"), which found that a company providing products and services primarily within the pharmaceutical industry was a "qualified trade or business" for purposes of Section 1202(e)(3).1 The IRS had never before issued guidance on the definition of "qualified small business stock" ("QSBS") under Section 1202.2 A private letter ruling is not binding on the IRS except as to the taxpayer that requested and received the ruling, and cannot be relied upon as precedent by other taxpayers. Nonetheless, a private letter ruling typically provides all taxpayers with some indication of the IRS position on the particular legal issue that was addressed in the context of the facts contained in the ruling.

BENEFITS OF SECTION 1202

Section 1202 allows an individual shareholder who has held QSBS for more than five years to receive tax-reduced or tax-free gain up to the greater of $10 million or 10 times the shareholder's basis in the QSBS.3 In order for a shareholder's stock to qualify as QSBS, it must have been issued by a "qualified small business" ("QSB") and it must have been acquired by the shareholder at original issuance (or in certain limited non-recognition transactions).4 Among other requirements, a corporation can be a QSB only if at least 80 percent of its assets are used in the active conduct of at least one "qualified trade or business."5 The Ruling is of particular interest because it gives substantive consideration to the meaning of the term "qualified trade or business."

QUESTIONS CONSIDERED IN THE RULING

The facts of the Ruling involved a company that operated in the pharmaceutical industry and aided clients in the commercialization of experimental drugs. The company's main business activities were researching the effectiveness of drug formulations, conducting clinical tests, and manufacturing drugs. The company also helped clients develop successful drug-manufacturing processes and solve other problems encountered in the pharmaceutical industry. The company's assets included manufacturing and clinical facilities along with intellectual property assets, such as a patent portfolio. The company also possessed several valuable relationships in the pharmaceutical industry.

The taxpayer in the Ruling had recently disposed of some stock in the company and asked the IRS to rule on whether the company was engaged in a "qualified trade or business" within the meaning of Section 1202(e)(3). Section 1202(e)(3) defines a "qualified trade or business" as any business other than a trade or business that:

  • involves performing services in the field of health, law, engineering, architecture, accounting, actuarial science, performing arts, athletics, financial services, brokerage services, or consulting;
  • has as its principal asset the reputation or skill of one or more of its employees;
  • operates in the field of finance, insurance, banking, investing, leasing, farming, or mining; or
  • runs a hotel, motel, restaurant, or similar business.

In analyzing whether the company was engaged in a "qualified trade or business" under Section 1202(e)(3), the IRS explained that "the thrust of § 1202(e)(3) is that businesses are not qualified trades or businesses if they offer value to customers primarily in the form of services, whether those services are the providing of hotel rooms, for example, or in the form of individual expertise (law firm partners)." The IRS noted that the company in the Ruling used its specific manufacturing and intellectual property assets to create value for customers, and was akin to a manufacturer of parts in the automobile industry. Accordingly, despite recognizing the company's clear connections to the pharmaceutical industry, which is a component of the "health" industry (a clearly prohibited field), the IRS ruled that the company's activities did not amount to the performance of services in the health industry within the meaning of Section 1202(e)(3). The Ruling specifically noted that the "Company is not in the business of offering service in the form of individual expertise."

POTENTIAL USEFULNESS OF THE RULING TO TAXPAYERS

The Ruling is significant because it should offer some insight into the government's general view of the meaning of "qualified trade or business" under Section 1202(e)(3). The plain language of the statute might have been read more broadly to exclude clinical testing and drug research as activities equivalent to the performance of services in the health industry. The Ruling's narrower interpretation of the exclusions in Section 1202(e)(3) at a minimum should provide many pharmaceutical companies with a favorable outlook as to their QSB eligibility.

The Ruling does not directly address the meaning of the language in Section 1202(e)(3) which excludes from the definition of "qualified trade or business" a company whose "principal asset . . . is the reputation or skill of one or more of its employees."6 Taxpayers frequently question the scope of this provision, wondering whether this phrase might encompass all start-up companies with few hard assets on their books because they must rely heavily on key employees to establish and maintain business value, or whether the term is limited to companies engaged in inherently service-based businesses.7 Although the Ruling does not provide a direct answer to this question, it does explain that the "reputation or skill" provision "works to exclude, for example, consulting firms, law firms, and financial asset management firms" and that the "thrust" of Section 1202(e)(3) is to exclude businesses whose primary value generator is services. Given the Owen case discussed in footnote 7 above, and the rationale of the Ruling, in appropriate circumstances it would seem reasonable for a start-up that is not engaged in one of the specifically excluded businesses to argue that it is a QSB even though it relies heavily on the skill and expertise of its employees, particularly where their efforts are necessary in order to develop valuable intangible assets that ultimately will go on to represent the bulk of the value of the company.

CONCLUSION

Section 1202 has often been criticized by commentators as not offering sufficient benefits to investors to justify its substantial limitations. However, legislative changes made in 2010 allow taxpayers who acquired QSBS between September 2010 and December 2013 to exclude 100 percent of their gain when they sell their QSBS, subject to the $10 million or 10-times-basis limits described above (and to avoid the AMT clawback). In addition, bills that have been introduced recently in the Senate would extend the 100 percent exclusion either temporarily or permanently.8 A temporary or permanent extension of the 100 percent gain exclusion, combined with a favorable definition of "qualified trade or business," definitely would make Section 1202 a more beneficial provision for entrepreneurs and investors who are considering how to form a new business venture.

This publication has been prepared for general informational purposes only. None of the statements made herein constitute financial, accounting, tax, or other professional advice of any kind. Please consult with your own advisors to discuss matters relevant to your specific situation.

Footnotes

1 P.L.R. 201436001 (May 22, 2014).

2 All Section or § references herein are to sections of the Internal Revenue Code of 1986, as amended, unless otherwise indicated.

3 See Section 1202(a)(1). Provided all of the other requirements are met, taxpayers who acquired QSBS before 2009 or after 2013 are eligible to exclude 50 percent of their gain from tax, subject to the alternative minimum tax ("AMT") clawback; those who acquired QSBS between February 2009 and September 2010 are eligible for 75 percent exclusion, subject to AMT clawback; and those who acquired QSBS between September 2010 and December 2013 are eligible for 100 percent gain exclusion, with no AMT clawback. As noted in the text accompanying footnote 8, infra, pending legislative proposals would reinstate the 100 percent gain exclusion either permanently or temporarily.

4 See Sections 1202(c)(1) and (h). For additional discussion of the requirements applicable to QSBS and Section 1202 generally, see MoFo Client Alert: Recent Changes Allow Tax-Free Receipt of up to $10 Million in Gain from the Sale of Small Business Stock, Jan. 17, 2013, available at http://media.mofo.com/files/Uploads/Images/130116-Sale-of-Small-Business-Stock.pdf; Bernie Pistillo and Maureen Linch, Recent Changes Make Qualified Small Business Stock Rules Attractive for Shares Acquired during 2013, NVCA Today, Feb. 25, 2013, available at http://nvcatoday.nvca.org/index.php/from-our-sponsors/recent-changes-make-qualified-small-business-stock-rules-attractive-for-shares-acquired-during-2013.html; David Strong, Section 1202 Qualified Small Business Stock, Aug. 11, 2011, available at http://media.mofo.com/files/Uploads/Images/110811-Section-1202-Qualified-Small-Business-Stock.pdf.

5 Section 1202(e)(1).

6 Section 1202(e)(3)(A).

7 The legislative history of Section 1202 also does not answer this question. The only authority we are aware of that discusses the point is a Tax Court memorandum opinion, John P. Owen, T.C. Memo. 2012-21, which in dicta dismisses an attempt by the government to disqualify a corporation as a QSB because of the importance of the founder's skill to the business. The case involved a company that created and sold insurance-related financial products. The founder was a seasoned insurance salesman with 40 years of experience in insurance sales. The IRS argued that the company did not qualify because of the "reputation or skill" language in Section 1202(e)(3) since the founder's skill was one of its principal assets of the business, but the court disagreed, explaining that even though the founder's skill did contribute to the success of the business, it was not an asset of the company.

8 The Expiring Provisions Improvement, Reform, and Efficiency Act of 2014, introduced on April 28, 2014, would extend the 100 percent gain exclusion to QSBS acquired until January 2016. S. 2260, 113th Cong. § 136 (2d Sess. 2014). The Buy it in America Act, introduced on July 29, 2014, would permanently extend the 100 percent gain exclusion to QSBS acquired any time after September 2010. S. 2680, 113th Cong. § 4 (2d Sess. 2014).

Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP. All rights reserved

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Maureen E. Linch
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions